Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non-Current Liabilities (2016 - 2018)

Historic Other Non-Current Liabilities for Fennec Pharmaceuticals (FENC) over the last 7 years, with Q2 2018 value amounting to $167000.0.

  • Fennec Pharmaceuticals' Other Non-Current Liabilities rose 20636.94% to $167000.0 in Q2 2018 from the same period last year, while for Jun 2018 it was $167000.0, marking a year-over-year increase of 20636.94%. This contributed to the annual value of $167000.0 for FY2017, which is 40606.06% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $167000.0 for Q2 2018, which was up 20636.94% from $167000.0 recorded in Q4 2017.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Non-Current Liabilities peaked at $5.5 million during Q1 2014, and registered a low of -$157000.0 during Q2 2017.
  • In the last 5 years, Fennec Pharmaceuticals' Other Non-Current Liabilities had a median value of $167000.0 in 2017 and averaged $1.2 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 234259.26% in 2014, then plummeted by 9734.21% in 2015.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $1.3 million in 2014, then tumbled by 93.78% to $82000.0 in 2015, then tumbled by 59.76% to $33000.0 in 2016, then soared by 406.06% to $167000.0 in 2017, then changed by 0.0% to $167000.0 in 2018.
  • Its last three reported values are $167000.0 in Q2 2018, $167000.0 for Q4 2017, and -$157000.0 during Q2 2017.